Oncolytics Biotech Inc T.ONC

Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

[Noteable]

Sigilon Therapeutics Inc. was trading at US$0.33 per share prior to its 1 for 13 reverse share split on May 22, 2023 that was follwed by Eli Lilly's offer to purchase the company for US$ 126.56 in cash on June 29, 2023 - a price increase of 38,251%.

https://ir.sigilon.com/news-releases/news-release-details/lilly-acquire-sigilon-therapeutics

CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock.

https://ir.sigilon.com/news-releases/news-release-details/sigilon-announces-reverse-stock-split-common-stock

[Noteable]

Sigilon Therapeutics Inc. is a pre-clinical company that is development of a "bio-platform". https://sigilon.com/pipeline/ 

[Noteable]

Should read: " ... pre-clinical company that is in development of a "bio-platform"

[Noteable]

Sigilon Therapeutics Inc. is a 'very-early stage' pre-clinical company that is in the conceptual development of a "bio-platform". This decsion fot Eli Lilly to acquire such an early stage company for US$126 per share further demonstrates that Big Pharma is facing a looming patent cliff and is seeking to fill its therapeutic product pipleline BUT is having to move further up

[Noteable]

Should read : ... " This decision of Eli Lilly to acquire such an early stage company for US$126 per share further demonstrates that Big Pharma is facing a looming patent cliff ...."

[fox7mf]

Seeing as we're so much further along, and derisked, where is our deal and how much should we expect, lol?!?

[Noteable]

With ONCY being a late- stage Phase 3 ready "bio-platform" company in 2 different therapeutic areas, with more ahead, we should be presently talking about ONCY being at the level of US$10 Billion to US$15 Billion in M&A valuation.

[fox7mf]

All of us, Matt Coffey included, expect CRC data to be at least as impressive as PDAC...a third possible ph3 indication, plus Car-t, plus MM...we could approach $15b +.

[Journeytc]

ONC dropped a planned phase 3 CRC trial several years ago to refocus on breast cancer after release of the surprising IND213 result.    So I'm sure CRC will be a great result on a smaller indication.   There's also more competition in this area.  Nevertheless it will be an important result building upon their story and credibility.  

[canadafan]

I looked over the Sigalon offer I'll give background, some important points & my thoughts as a comparable. Bacground;Sigalon  1.Sigalon has only pre- clical studies. Not even any phase 1. 2. Before the deal they were trading @ just around $4ps. 3. The offer is $14.28ps + future considerations ( biobucks), totalling $112/ps. 4. Sigalon is trading around $21, above the cash offer.

[fox7mf]

Decent volume and + as much as $0.30 usd this morning. 

[canadafan]

Very possibly close above $3 usd on the NAS today. About $4 CDN equivalent 

[Allinvest]

It is alteady above 3$ us. Most be very good news in n'est futur!

[canadafan]

Being above $3 Nas is one thing. Closing above $3 is a recently new indicator. with 15 min to go, the Nas price is again gaining strength. A clear sign we/ I have not seen in a long time. Anyone following does know " news within 90 days" now 80 days, regarding a phase 3 entry & most likely a partership. So yes something is going on. want some good returns, buy, hold & wait. 80

[fox7mf]

It closed above $3 at 1pm.

[fox7mf]

 Yeah, it's looking like 1.7m volume and around a $3.15usd close. There may be some evidence that Adlai Nortye is looking at an IPO. We'll see!!

[Noteable]

For fox7mf : Eli Lilly's offer to purchase the company for US$ 126.56 in cash on June 29, 2023 - a price increase of 38,251%.

[Noteable]

Repost - Sigilon Therapeutics Inc. is a 'very-early stage' pre-clinical company that is in the conceptual development of a "bio-platform". This decsion fot Eli Lilly to acquire such an early stage company for US$126 per share further demonstrates that Big Pharma is facing a looming patent cliff and is seeking to fill its therapeutic product pipleline BUT is

[Noteable]

Big Pharma is facing a looming patent cliff and is seeking to fill its therapeutic product pipleline BUT is having to move further up-stream in the product development process in order to obtain biological assets that are experiecing favorable treatment by the Inflation Reduction Act (IRA) as already outlined in earlier posts.  So what some may consider to be an exception, the kind of

[Noteable]

And no stinkin NPV calculations pre-determined the acquisition of Sigilon Therapeutics Inc . ... Eli Lillys looming patent cliff did.

[Noteable]

M&A activity the last 2 years had Big Pharma sitting on the sidelines, however a looming patent cliff has Big Pharma gearing up their M&A activities as recently seen by Big Pharma's "all-in" acquisitions. 

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?threadid=35680287

[Noteable]

One example. Read the thread.